The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1338
Which TNF Inhibitor for Rheumatoid Arthritis?
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved five tumor necrosis factor (TNF) inhibitors for treatment of moderately to severely active rheumatoid arthritis (RA). TNF-α is a pro-inflammatory cytokine involved in the pathogenesis of many systemic inflammatory disorders.

TREATMENT OF RHEUMATOID ARTHRITIS — Disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate are now used early in the treatment of RA to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal antiinflammatory drugs (NSAIDs) and corticosteroids. Biologic DMARDs, particularly the TNF inhibitors, are generally reserved for use in moderate to severe disease.1

EFFICACY — Among RA patients who have not responded to methotrexate, addition of a TNF inhibitor has usually resulted in an ACR20 response (>20% improvement) in 55%-70% of patients in controlled trials2,3 There ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Which TNF Inhibitor for Rheumatoid Arthritis?
Article code: 1338b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian